Annual Report (10-k)

Date : 03/29/2019 @ 8:19PM
Source : Edgar (US Regulatory)
Stock : Kraig Biocraft Laboratories, Inc. (QB) (KBLB)
Quote : 0.249  0.037 (17.45%) @ 9:01PM

Annual Report (10-k)

 
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 10-K
 
(Mark One)
 
  ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For The Fiscal Year Ended December 31, 2018
 
  TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
Commission File No. 333-146316
 
KRAIG BIOCRAFT LABORATORIES, INC.
(Exact name of issuer as specified in its charter)
 
Wyoming
 
83-0459707  
(State or Other Jurisdiction of Incorporation)
 
(I.R.S. Employer Identification No.)
 
2723 South State St. Suite 150
Ann Arbor, Michigan 48104
 
(734) 619-8066
(Address of Principal Executive Offices)
 
(Registrant s Telephone Number)
 
Securities registered under Section 12(b) of the Exchange Act:   None.
 
Securities registered under Section 12(g) of the Exchange Act:   None.
 
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes   No     
 
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes   No   
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes    No   
 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T ( § 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes    No   
 
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K ( § 229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant s knowledge, in definitive proxy or information statements incorporated by reference Part III of this Form 10-K or any amendment to this Form 10-K.      
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company and “emerging growth company” in Rule 12b-2 of the Exchange Act.
 
Large accelerated filer    
Accelerated filer    
Non-accelerated filer   
Smaller reporting company  
Emerging growth company  
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes    No   
 
The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant on June 30, 2018 (the last business day of the registrant’s most recently completed second fiscal quarter) was approximately $34,905,672.   The aggregate market value was computed by reference to the last sale price ($0.058 price per share) of such common equity as of that date.
 
As of March 29, 2019, the registrant had 835,733,840 shares of common stock issued and outstanding.
 
 
1
 
 
  INTRODUCTORY NOTE
 
Kraig , Kraig Biocraft KBLB , the Company , we , us and our refer to Kraig Biocraft Laboratories, Inc., a Wyoming corporation, unless the context otherwise requires.
 
Special Note Regarding Forward-Looking Statements
 
This report contains forward-looking statements and information that are based on the beliefs of our management as well as assumptions made by and information currently available to us. Such statements should not be unduly relied upon. Forward-looking statements include statements about our expectations, beliefs, plans, objectives, intentions, assumptions and other statements that are not historical facts or that are not present facts or conditions. Forward-looking statements and information can generally be identified by the use of forward-looking terminology or words, such as anticipate, approximately, believe, continue, estimate, expect, forecast, intend, may, ongoing, pending, perceive, plan, potential, predict, project, seeks, should, views or similar words or phrases or variations thereon, or the negatives of those words or phrases, or statements that events, conditions or results can, will, may, must, would, could or should occur or be achieved and similar expressions in connection with any discussion, expectation or projection of future operating or financial performance, costs, regulations, events or trends. The absence of these words does not necessarily mean that a statement is not forward-looking.
 
Forward-looking statements and information are based on management s current expectations and assumptions, which are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict. These statements reflect our current view concerning future events and are subject to risks, uncertainties and assumptions. There are important factors that could cause actual results to vary materially from those described in this report as anticipated, estimated or expected, including, but not limited to, those factors and conditions described under Item 1A. Risk Factors as well as general conditions in the economy, petrochemicals industry and capital markets, Securities and Exchange Commission (the SEC ) regulations which affect trading in the securities of penny stocks, and other risks and uncertainties. Except as required by law, we assume no obligation to update any forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in any forward-looking statements, even if new information becomes available in the future. Depending on the market for our stock and other conditional tests, a specific safe harbor under the Private Securities Litigation Reform Act of 1995 may be available. Notwithstanding the above, Section 27A of the Securities Act of 1933, as amended (the Securities Act ), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act ), expressly state that the safe harbor for forward-looking statements does not apply to companies that issue penny stock. Because we may from time to time be considered to be an issuer of penny stock, the safe harbor for forward-looking statements may not apply to us at certain times.
 
2
 
  
TABLE OF CONTENTS
 
 
 
 Page
 
PART I
 
 
 
 
 
 
 
 
 
ITEM 1.
DESCRIPTION OF BUSINESS
    4
 
ITEM 1A.
RISK FACTORS
    8
 
ITEM 1B.
UNRESOLVED STAFF COMMENTS
    8
 
ITEM 2.
DESCRIPTION OF PROPERTY
    8
 
ITEM 3.
LEGAL PROCEEDINGS
    8
 
ITEM 4.
MINE SAFETY DISCLOSURES
    8
 
 
       
PART II
 
       
 
       
ITEM 5.
MARKET FOR REGISTRANT S COMMON EQUITY; RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES
    8
 
ITEM 6.
SELECTED FINANCIAL DATA
    9
 
ITEM 7.
MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
    9
 
ITEM 7A.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
    13
 
ITEM 8.
FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
    13
 
ITEM 9.
CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
    34
 
ITEM 9A.
CONTROLS AND PROCEDURES
    34
 
ITEM 9B.
OTHER INFORMATION
    35
 
 
       
PART III
 
       
 
       
ITEM 10.
DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
    35
 
ITEM 11.
EXECUTIVE COMPENSATION
    37
 
ITEM 12.
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
    39
 
ITEM 13.
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
    39
 
ITEM 14.
PRINCIPAL ACCOUNTANT FEES AND SERVICES
    40
 
 
       
PART IV
 
       
 
       
ITEM 15.
EXHIBITS
    41
 
 
       
SIGNATURES
 
    43   
 
 
 
3
 
 
PART I
 
ITEM 1. DESCRIPTION OF BUSINESS.
 
Overview
 
Kraig Biocraft Laboratories, Inc. is a corporation organized under the laws of Wyoming on April 25, 2006. We were organized to develop high strength fibers using recombinant DNA technology, for commercial applications in both the specialty fiber and technical textile industries. Specialty fibers are engineered for specific uses that require exceptional strength, flexibility, heat resistance and/or chemical resistance. The specialty fiber market is exemplified by two synthetic fiber products: aramid fibers and ultra-high molecular weight polyethylene fiber. The technical textile industry involves products for both industrial and consumer products, such as filtration fabrics, medical textiles (e.g., sutures and artificial ligaments), safety and protective clothing and fabrics used in military and aerospace applications (e.g., high-strength composite materials).
 
We are using genetic engineering technologies to develop fibers with greater strength, resiliency and flexibility for use in our target markets, namely the textile, specialty fiber and technical textile industries.
 
The Report of Independent Registered Public Accounting Firm to our financial statements as of December 31, 2018 include an explanatory paragraph stating that  our net loss from operations and net capital deficiency  at December 31, 2018 raise substantial doubt about our ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
 
The Product
 
Certain fibers produced in nature possess unique mechanical properties in terms of strength, resilience and flexibility.
 
Comparison of the Properties of Spider Silk and Steel
 
 
 
Material Toughness (1)
 
 
Tensile Strength (2)
 
 
Weight (3)
 
Dragline spider silk
    120,000-160,000  
    1,100-2,900  
    1.18-1.36  
 
       
       
       
Steel
    2,000-6,000  
    300-2,000  
    7.84  
 
    1  
  Measured by the energy required to break a continuous filament, expressed in joules per kilogram (J/kg). A .357 caliber bullet has approximately 925 joules of kinetic energy at impact.
    2  
  Tensile strength refers to the greatest longitudinal stress the fiber can bear, measured by force over area in units of newtons per square meter. The measurement here is in millions of pascals.
    3  
  In grams per cubic centimeter of material.
 
This comparison table was the result of research performed by Randolph Lewis, Ph.D. at the University of Wyoming. Such work was summarized in an article entitled Spider Silk: Ancient Ideas for New Biomaterials which was published in Chemicals Review, volume 106, issue 9, pages 3672 3774. The measurements in joules in the table above are a conversion from Dr. Lewis measurements in newtons/meter squared.
 
We believe that the genetically engineered protein-based fibers we seek to produce have properties that are in some ways superior to the materials currently available in the marketplace. For example, as noted above, the ability of spider silk to absorb in excess of 100,000 joules of kinetic energy per kilogram makes it a potentially ideal material for structural blast protection.
 
Production of this material in commercial quantities holds the potential of a life-saving ballistic resistant material, which is lighter, thinner, more flexible, and tougher than steel. Other applications for spider silk based recombinant fibers include use as structural material and for any application in which light weight and high strength are required. We believe that fibers made with recombinant protein-based polymers will make significant inroads into the specialty fiber and technical textile markets.
 
Our Technology
 
While scientists have been able to replicate the proteins that are the building blocks of spider silk, the technological barrier that has stymied production until now has been the inability to form these proteins into a fiber with the desired mechanical characteristics and to do so in a cost effective manner.
 
We have licensed the right to use the patented genetic sequences and genetic engineering technology developed in university laboratories. The Company has been working collaboratively with university laboratories to develop fibers with the mechanical characteristics of spider silk. We are applying this proprietary genetic engineering technology to domesticated silkworms, which are already the most efficient commercial producers of silk.
 
 
4
 
Our technology builds upon the unique advantages of the domesticated silkworm for this application. The silkworm is ideally suited to produce recombinant protein fiber because it is already an efficient commercial and industrial producer of protein based polymers. Forty percent (40%) of the caterpillars weight is devoted to the silk glands. The silk glands produce large volumes of protein, called fibroin, which are then spun into a composite protein thread (silk).
 
We are working to use our genetic engineering technology to create recombinant silk polymers. On September 29, 2010, we jointly announced with the University of Notre Dame the success of our collaborative research with Notre Dame in creating approximately twenty different strains of transgenic silkworm which produce recombinant silk polymers. In April 2011, we entered into a licensing agreement with Sigma-Aldrich which provides us the use of Sigma-Aldrich s zinc finger technology to accelerate and enhance our product development.
 
A part of our intellectual property portfolio is the exclusive right to use certain patented spider silk gene sequences in silkworm. Under the Exclusive License Agreement with the University of Wyoming, we have obtained certain exclusive rights to use numerous genetic sequences which are the subject of US patents.
 
The introduction of the gene sequence, in the manner employed by us, results in a germline transformation and is therefore self-perpetuating. This technology is in essence a protein expression platform which has other potential applications including diagnostics and pharmaceutical production.
 
Collaborative Research and Licensing
 
In May 2006, the Company entered into a licensing agreement with the University Of Wyoming, which granted the Company the exclusive global rights to use and commercialize patented genetic sequences in silkworm.    In exchange for this license the University of Wyoming received $10,000 cash payment and the University of Wyoming Foundation received 17,500,000 shares of the Company s common stock. Under the terms of the licensing agreement, the Company is obligated to provide annual license fees of $10,000 and support the University research with $13,700 annually.   As of today, the Company is current on the $10,000 per year payment and are accruing the $13,700 annual payments. No royalties are required. This agreement has remained unchanged since 2006.    The Company has not signed any other agreements with the University of Wyoming.  
 
In 2007, the Company entered into the first of a series of collaborative research agreements with the University of   Notre Dame ( Notre Dame ). The Company provides financial support to ongoing research and development of transgenic silkworms and the creation of recombinant silk fibers. In exchange, the Company has an option to obtain the exclusive global commercialization rights to the technology developed pursuant to the research effort.
 
Following the first collaborative research agreement, the Company entered into successive licensing and collaborative research agreements to provide different levels of financial support.    The trend has been for an increase in financial support for the research and development in nearly every successive agreement.    In June 2012, we entered into an Intellectual Property / Collaborative Research Agreement with Notre Dame ( 2012 Notre Dame Research Agreement ). On March 4, 2015, we entered into a new Intellectual Property / Collaborative Research Agreement with Notre Dame extending the agreement through March 2016 ( 2015 Notre Dame Research Agreement ). Under the 2015 Notre Dame Research agreement, the Company provided approximately $534,000 in financial support. On September 20, 2015, the 2015 Notre Dame Research Agreement was amended to increase the total funding by approximately $179,000;in February 2016, the agreement was extended to July 31, 2016 and in August 2016, the agreement was extended to December 31, 2016. In May 2017, the 2015 Notre Dame Research Agreement was amended to increase the total funding by approximately $189,000   and the duration of the agreement was extended to September 30, 2017. The Company has not extended the 2015 Notre Dame Research Agreement after September 30, 2017, but may negotiate a new collaborative research agreement with the Notre Dame in 2019 at reduced levels of funding.
 
In 2011, the Company exercised its option to obtain the global commercialization rights to the technology developed under the collaborative research agreements with Notre Dame, which resulted in a separate license agreement with Notre Dame (the “ 2011 ND Agreement ”).    Pursuant to the 2011 ND Agreement, Notre Dame filed an international patent application and numerous national patent applications on technology relating to the creation and use of recombinant spider silks and the Company received exclusive and non-exclusive rights to certain spider silk technologies including commercial rights with the right to sublicense such intellectual property. The 2011 ND Agreement obligates the Company to reimburse Notre Dame for costs associated with the filing, prosecuting and maintaining of such patents and patent applications.    In exchange for the rights to commercialization, Notre Dame has received 2,200,000 shares of the Company s common stock and the Company has agreed to pay Notre Dame royalties of 2% of the Company s gross sales of the licensed products and 10% of any sublicensing fees received by the Company on licensed technology. The Company has also agreed to pay to Notre Dame $50,000 a year, which will be reduced from the total amount of royalties paid in the same year. The $50,000 payment to Notre Dame is not owed for any year in which the Company is sponsoring research within Notre Dame.
 
On October 15, 2013, the Company entered into an intellectual property agreement with a scientific researcher relating to the development of new recombinant silk fibers.    Under the terms of that agreement, the scientific researcher would transfer to the Company his rights of intellectual property, inventions and trade secrets which the researcher develops relating to recombinant silk.    The researcher received 8,000,000 common stock warrants from the Company, exercisable 24 months from the date of the agreement.    The researcher would also receive additional warrants when and if the researcher develops advanced recombinant silk fibers for the Company s use.    Under the terms of the agreement, the researcher would receive 10,000,000 warrants in the event that he develops a new recombinant silk fiber with certain performance characteristics, and another 10,000,000 warrants if he develops a second recombinant silk fiber with certain characteristics.    If the researcher performs the contract in good faith the consultant will be entitled to an additional 8,000,000 warrants on the two year anniversary of the agreement.    The researcher received the 10,000,000 warrants for the creation of a new transgenic meeting performance characteristics and a warrant of 8,000,000 for performance of the contract in good faith. The warrants described   above all contain a cashless exercise provision and are exercisable on the 24 month anniversary of the date on which they were issuable under the agreement.
 
On December 30, 2015, the Company entered into a cooperative agreement for the research and pilot production of hybrid silkworms in Vietnam.   On May 1, 2018, the Company was issued its Enterprise Registration Certificate (“ERC”) so that it can begin its operations in Vietnam. The Company has established a subsidiary in Vietnam where it will develop and produce hybrid silkworms. Management believes the ERC puts the Company on a path to scale to a much greater level by harnessing existing silk production infrastructure with the capacity to match the demand for their spider silk materials.
 
5
 
 
As of the date of this Report, the Company’s research and development efforts are focused on growing their internal capabilities, but will consider renewing funding of the collaborative research and development of high strength polymers at Notre Dame in 2019. The Company has been actively pursuing the development of the commercial scale production of their recombinant materials including Monster Silk® and Dragon Silk TM . Additionally, the Company plans to accelerate both their microbiology and selective breeding programs, as well as providing more resources for their material testing protocols in 2019.
 
The Market
 
We are focusing our work on the creation of new fibers with unique properties including fibers with potential high performance and technical fiber applications. The performance fiber market is exemplified by two classes of product: aramid fibers, and ultra-high molecular weight polyethylene fiber. These products service the need for materials with high strength, resilience, and flexibility. Because these synthetic performance fibers are stronger and tougher than steel, they are used in a wide variety of military, industrial, and consumer applications.
 
Among the users of performance fibers are the military and police, which employ them for ballistic protection. The materials are also used for industrial applications requiring superior strength and toughness, i.e. critical cables and abrasion/impact resistant components. Performance fibers are also employed in safety equipment, high strength composite materials for the aero-space industry and for ballistic protection by the defense industry.
 
The global market for technical textiles was estimated at greater than $234 billion in 2017. 1
 
1 https://www.alliedmarketresearch.com/technical-textile-market
 
These are industrial materials which have become essential products for both industrial and consumer applications. The market for technical textiles can be defined as consisting of:
 
Medical textiles;
Geotextiles;
Textiles used in Defense and Military;
Safe and Protective Clothing;
Filtration Textiles;
Textiles used in Transportation;
Textiles used in Buildings;
Composites with Textile Structure;
Functional and Sportive Textiles.
 
We believe that the superior mechanical characteristics of the next generation of protein-based polymers (in other words, genetically engineered silk fibers), will open up new applications for the technology. The materials which we are working to produce are many times tougher and stronger than steel. These fibers are often referred to as super fibers.
 
The Company
 
Kraig Biocraft Laboratories, Inc. (Kraig) is a Wyoming corporation. Our shares are traded on the OTCQB under the ticker symbol:   KBLB . There are 835,733,840 shares of common stock issued and outstanding as of March 29, 2019; Kim Thompson, our founder and CEO, owns approximately 27.01% of such common shares. There are 2 shares of super voting preferred stock issued and outstanding as of   March 29, 2019, all of which Kim Thompson owns.
 
The inventor of our technology concept, Kim Thompson, is the founder of Kraig Biocraft Laboratories, Inc. Our protein expression system is, in concept, scalable, cost effective, and capable of producing a wide range of proteins and materials.
 
In 2006, the Company entered into a licensing agreement with the University Of Wyoming, which granted the Company the exclusive global rights to use and commercialize patented genetic sequences in silkworm.  In exchange for this license, the University of Wyoming received $10,000 cash payment and the University of Wyoming Foundation received 17,050,000 shares of the Company’s common stock. Under the terms of the licensing agreement, the Company is obligated to provide annual license fees of $10,000 and support the University’s research with $13,700 annually. As of the date of this Report, the Company is current on the $10,000 per year payment, but has been accruing the $13,700 payments since 2006. No royalties are required under the agreement. This agreement has remained unchanged since 2006.  
 
On April 8, 2011, Kraig and Sigma-Aldrich Co., an Illinois corporation ( Sigma ) entered into a License and Option Agreement. Under the terms of the agreement, Sigma will provide Kraig with its proprietary genetic engineering tools and expertise in zinc finger nuclease to enable Kraig to significantly accelerate its product development. In addition to providing the customized tools and technological know-how, Sigma has granted Kraig an option for a commercial license to use the technology in the textile, technical textile and biomedical markets. Sigma will create customized zinc fingers for Kraig's use in its development of spider silk polymers and technical textiles.
 
In September 2010, the Company announced that it had succeeded in introducing spider silk DNA in silkworm with the result that the transgenic silkworm were producing new recombinant silk fibers. These fibers are a combination of natural silkworm silk proteins and proteins that the silkworms are making as a result of the introduction of the spider silk DNA. The Company announced that it had created approximately twenty different transgenic silkworm strains producing recombinant silk.
 
6
 
 
We entered into an intellectual property collaborative research agreement with the University of Notre Dame in 2007. That agreement was subsequently extended and expanded to include research and development of certain platform technologies with potential applications for diagnostics and pharmaceutical production. On March 20, 2010, the Company extended its agreement with Notre Dame through February 28, 2011 .   Pursuant to these agreements the genetic work has been conducted primarily within Notre Dame s laboratories. In June 2012, we entered into a Collaborative Research Agreement with Notre Dame ( 2012 Notre Dame Research Agreement ).   On March 4, 2015, we entered into a new Collaborative Research Agreement with University of Notre Dame extending the agreement through March 2016 ( 2015 Notre Dame Research Agreement ).    Under the 2015 Notre Dame Research agreement, the Company provided approximately $534,000 in financial support.   On September 20, 2015, this agreement was amended to increase the total funding by approximately $179,000;in February 2016, this agreement was extended to July 31, 2016 and in August 2016 this agreement was extended to December 31, 2016. In May 2017, the 2015 Notre Dame Agreement was amended to increase the total funding by approximately $189,000 and the duration of this agreement was extended to September 30, 2017. The Company did not extend the agreement after September 30, 2017.   The Company will consider negotiating a new Collaborative Research Agreement with the University of Notre Dame in 2019 at reduced levels of funding. For the year ended December 31, 2018 and 2017, respectively, the Company paid $0 and $258,892 in research and development fees.
 
License Agreements/Intellectual Property
 
We have obtained certain rights to use a number of university created, and patented, spider silk proteins, gene sequences and methodologies.
 
Between 2010 and 2014 the University of Notre Dame filed approximately twelve patent applications pursuant to our intellectual property and collaborative research agreement.    Under the terms of that agreement the Company has an option for the exclusive commercial rights to that technology. The Company has notified the University of its exercise of that option.    These patent applications include coverage in the United States, Europe, South Korea, Vietnam, Brazil, India, China, Australia, Japan, and Canada.  As of the date hereof, two patents have been issued, number 10-1926286 in South Korea and number 2011314072 in Australia, all remaining patents applications are still in process .
  
In 2014, seven trademarks were issued to the Company which it intends to use for product branding in the future. The details of such trademarks are set forth in the following table:
 
Marks
Registered Owner
Country
Status
Monster SilkTM
Kraig Biocraft Laboratories
United States of America
issued
SpiderpillarTM
Kraig Biocraft Laboratories
United States of America
issued
SpilkTM
Kraig Biocraft Laboratories
United States of America
issued
Monster WormTM
Kraig Biocraft Laboratories
United States of America
issued
Spider WormTM
Kraig Biocraft Laboratories
United States of America
issued
Spider MothTM
Kraig Biocraft Laboratories
United States of America
issued
 
License Agreement with Notre Dame University
 
As previously stated, in 2011, the Company exercised its option to obtain the global commercialization rights to the technology developed under the collaborative research agreements with Notre Dame, which resulted in a separate license agreement with Notre Dame.    Pursuant to that license agreement, Notre Dame has filed an international patent application and numerous national patent applications on technology relating to the creation and use of recombinant spider silks.    The license agreement obligates the Company to reimburse Notre Dame for costs associated with the filing, prosecuting and maintaining of such patents and patent applications.   The license agreement has a term of 20 years which can be extended on an annual basis after that. It can be terminated by the University of Notre Dame if the Company defaults on its obligations under the agreement and fails to cure such default within 90 days of a written notice by the university. The Company may terminate the agreement upon a 90 day written notice subject to payment of a termination fee of $5,000 if the termination takes place within 2 years after its effectiveness, $10,000 if the termination takes place within 4 years after its effectiveness and $20,000 if the Agreement is terminated after 4 years. 
 
Exclusive License Agreement with University of Wyoming
 
In May 2006, we entered into a license agreement with the University of Wyoming, pursuant to which we have licensed the right to commercialize the production by silkworms of certain synthetic and natural spider silk proteins and the genetic sequencing for such spider silk proteins. These spider silk proteins and genetic sequencing are covered by patents held by the University of Wyoming. Our license allows us only to use silkworms to produce the licensed proteins and genetic sequencing. We have the right to sublicense the intellectual property that we license from the University of Wyoming. Our license agreement with the University of Wyoming requires that we pay licensing and research fees to the university in exchange for an exclusive license in our field of use for certain university-developed intellectual property including patented spider silk gene sequences. Pursuant to the agreement, we issued 17,500,000 shares of our Class A common stock to the University Foundation. Our license agreement with the University of Wyoming will continue until the later of (i) expiration of the last-to-expire patent we license from the University of Wyoming under this license agreement in such country or (ii) ten years from the date of first commercial sale of a licensed product in such country. There are no royalties payable to the University of Wyoming under the terms of our agreement with them.
 
We anticipate making arrangements with the University of Wyoming to address accrued fees. If we fail to make such arrangements the University of Wyoming could terminate our license agreement. We anticipate that such a termination would result in a loss of one to three months of research time and result in increased research and development costs in the range of $20,000 to $60,000.  
 
 
7
 
Research and Development
 
On September 29, 2010 we announced that we had achieved our longstanding goal of producing new silk fibers composed of recombinant proteins. The Company intends to turn our technology to the development and production of high performance polymers .
 
During the fiscal years ended December 31, 2018 and 2017, we have spent approximately 13,160 hours and   8,200 hours, respectively, on research and development activities, which consisted primarily of laboratory research on genetic engineering by our in-house research operations and outside consultants pursuant to our collaborative research agreement with the University of Notre Dame in 2017..
 
Employees
 
As of the date of this filing, we have 9 employees including Kim Thompson, our sole officer and director and Jonathan R. Rice, our Chief Operating Officer.   We plan to hire more persons on as-needed basis.
 
ITEM 1A. RISK FACTORS.
 
As the Company is a smaller reporting company, this item is  not applicable.
 
ITEM 1B. UNRESOLVED STAFF COMMENTS.
 
As the Company is a smaller reporting company, this item is  not applicable.
 
ITEM 2. DESCRIPTION OF PROPERTY.
 
Starting in September of 2015, we rent office space at 2723 South State Street, Suite 150, Ann Arbor, Michigan 48104, which is our principal place of business. We pay an annual rent of $2,328 for conference facilities, mail, fax, and reception services located at our principal place of business.
 
Starting in February of 2015, we rent additional office space in East Lansing, Michigan and currently pay a monthly rent of $432 for office space, conference facilities, mail, fax, and reception services. This lease ended in October of 2017.
 
Starting in July of 2016, we rent factory space in South Bend, Indiana with a monthly rent of $670. This lease ended in November of 2017.
 
On January 23, 2017, the Company signed an 8 year property lease with the Company s President for land in Texas where the Company grows its mulberry. The Company pays a monthly rent of $960. Rent expense related party for the year ended December 31, 2018 and 2017 was $11,520 and $10,560, respectively.
 
On September 13, 2017, the Company signed a new two year lease commencing on October 1, 2017 and ending on September 30, 2019. The Company pays an annual rent of $39,200 for the year one of lease and $42,000 for the year two of lease for office and manufacturing space.     For the year ended December 31, 2018 and 2017 the Company paid $46,433 and $9,800 respectively, for office and manufacturing space.
 
  ITEM 3. LEGAL PROCEEDINGS.
 
We may from time to time become a party to various legal or administrative proceedings arising in the ordinary course of our business.
 
To the knowledge of our management,   we are currently not a party to any material legal or administrative proceedings and are not aware of any pending or threatened legal or administrative proceedings against us.    
 
ITEM 4. MINE SAFETY DISCLOSURES.
 
As the Company is a smaller reporting company, this item is  not applicable.
 
PART II
 
ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.
 
Market Information
 
Our common stock trades on the OTCQB system under the symbol KBLB . Our CUSIP number is 50075W.
 
Holders
 
As of March 29, 2019 in accordance with our transfer agent records, we had 30 record holders of our Class A common stock and 0 holders of our Class B common stock. This number excludes any estimate by us of the number of beneficial owners of shares held in street name, the accuracy of which cannot be guaranteed.
 
 
8
 
Transfer Agent and Registrar
 
Our transfer agent is Olde Monmouth Stock Transfer Co., Inc., 200 Memorial Parkway, Atlantic Highlands, NJ    07716 and its phone number is (732) 872-2727.
 
Sale of Unregistered Securities
 
Information regarding any equity securities we have sold during the period covered by this Report that were not registered under the Securities Act of 1933, as amended, is set forth below. Each such transaction was exempt from the registration requirements of the Securities Act by virtue of Section 4(a)(2) of the Securities Act or Rule 506 of Regulation D promulgated by the SEC, unless otherwise noted. Unless stated otherwise: (i) the securities were offered and sold only to accredited investors; (ii) there was no general solicitation or general advertising related to the offerings; (iii) each of the persons who received these unregistered securities had knowledge and experience in financial and business matters which allowed them to evaluate the merits and risk of the receipt of these securities, and that they were knowledgeable about our operations and financial condition; (iv) no underwriter participated in, nor did we pay any commissions or fees to any underwriter in connection with the transactions; and, (v) each certificate issued for these unregistered securities contained a legend stating that the securities have not been registered under the Securities Act and setting forth the restrictions on the transferability and the sale of the securities.
 
On January 25, 2017, the Company issued 750,000 shares of common stock to a consultant for services rendered.  
 
On February 6, 2017 the Company issued a warrant for 750,000 share of common stock to a consultant for services rendered.
 
On June 20, 2017 the Company granted 14,745,203 shares in connection with the cashless exercise of the 15,000,000 warrants. The shares were issued on July 14, 2017.
 
On June 26, 2017, the Company issued 2-year warrant to purchase 15,000,000 shares of common stock at an exercise price of $0.001 per share to a consultant for services rendered. The warrants had a fair value of $848,011, based upon the Black-Scholes option-pricing model on the date of grant and are fully vested on the date granted.  Warrants became exercisable on December 26, 2017, and for a period of 2 years expiring on June 26, 2019. During the year ended December 31, 2017, the Company recorded 848,011 as an expense for warrants issued.
 
On December 27, 2017, the Company granted 14,651,162 shares in connection with the cashless exercise of the 15,000,000 warrants. The shares were issued on December 29, 2017.
 
On February 9, 2018, the Company issued 3-year warrant to purchase 3,000,000 shares of common stock at an exercise price of $0.056 per share to a consultant for services rendered. The warrants had a fair value of $52,660, based upon the Black-Scholes option-pricing model on the date of grant and are fully vested on the date granted.  Warrants will be exercisable on August 9, 2019, and for a period of 2 years expiring on August 9, 2021. During the year ended December 31, 2018, the Company recorded 52,660 as an expense for warrants issued.
 
On March 20, 2018, the Company issued 4-year warrant to purchase 600,000 shares of common stock at an exercise price of $0.001 per share to a consultant for services rendered. The warrants had a fair value of $19,915, based upon the Black-Scholes option-pricing model on the date of grant and are fully vested on March 20, 2018.  Warrants will be exercisable on March 20, 2019, and for a period of 3 years expiring on March 20, 22. During the year ended December 31, 2018, the Company recorded 19,915 as an expense for warrants issued.
 
On April 6, 2018, the Company issued 36,000 shares with a fair value of $1,076 ($0.0299/share) to a consultant as consideration for consulting fees owed from October 1, 2014 through June 30, 2018 in the amount of $21,000.
 
Repurchases of Equity Securities
 
None.
 
ITEM 6. SELECTED FINANCIAL DATA
 
As the Company is a smaller reporting company, this item is  not applicable.
 
ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
 
Caution Regarding Forward-Looking Information
 
The following discussion and analysis of our financial condition and result of operations should be read in conjunction with our audited consolidated financial statements and the notes to those financial statements appearing elsewhere in this Form 10-K. This discussion contains forward-looking statements and involves numerous risks and uncertainties contained in this report and the other reports we file with the Securities and Exchange Commission. Our actual results may differ materially from those contained in any forward-looking statements.
 
Plan of Operations
 
During the next twelve months, we expect to take the following steps in connection with the further development of our business and the implementation of our plan of operations:
 
We plan to accelerate both our microbiology and selective breeding programs as well as providing more resources for our material testing protocols into 2019. We spent approximately $148,069 over the last 12 months on research and development of high strength polymers. In 2018 we directed our research and development efforts on growing our internal capabilities. We will consider renewing funding of the collaborative research and development of high strength polymers at the University of Notre Dame in 2019.
 
 
9
 
 
 
 
 
   ● 
We expect to spend approximately $13,700 on collaborative research and development of high strength polymers and spider silk protein at the University of Wyoming over the next twelve months. This level of research spending at the university is also a requirement of our licensing agreement with the university.
 
 
 
 
   ●
We plan to complete renovations of our Quang Nam, Vietnam factory and begin commercial scale production of our recombinant spider silk in Vietnam according to our investment and enterprise registration certificates.
 
 
 
 We will consider buying an established revenue producing company in a compatible business, in order to broaden our financial base and facilitate the commercialization of our products. We expect to use a combination of stock and cash for any such purchase.
 
 
 
 
We will also actively consider pursuing collaborative research opportunities with both private and university laboratories in areas of research which overlap the company’s existing research and development. One such potential area for collaborative research which the company is considering is protein expression platforms. If our financing allows, management will give strong consideration to increasing the breadth of our research to include protein expression platform technologies.
 
 
 
 
We plan to actively pursue collaborative research and product testing, opportunities with companies in the biotechnology, materials, textile and other industries.
 
 
 
 
We plan to actively pursue collaborative commercialization, marketing and manufacturing opportunities with companies in the textile and material sectors for the fibers we developed and for any new polymers that we create in 2019.
 
 
 
 
We plan to actively pursue the development of commercial scale production of our recombinant materials including Monster Silk ®  and Dragon SilkTM.
 
Limited Operating History
 
We have not previously demonstrated that we will be able to expand our business through an increased investment in our research and development efforts. We cannot guarantee that the research and development efforts described in this filing will be successful. Our business is subject to risks inherent in growing an enterprise, including limited capital resources, risks inherent in the research and development process and possible rejection of our products in development.
 
If financing is not available on satisfactory terms, we may be unable to continue our research and development and other operations. Equity financing will result in dilution to existing shareholders.
 
Results of Operations for the Years ended December 31, 2018 and 2017.
 
Our revenue, operating expenses, and net loss from operations for the years ended December 31, 2018 as compared to the year ended December 31, 2017, were as follows some balances on the prior period s combined financial statements have been reclassified to conform to the current period presentation:
 

 
Year Ended
 
     
 
% Change
 
 
 
    December 31  
 
 
Increase (Decrease)
 
 
 
 
 
 
2018
 
 
2017
 
 
Change
 
 
 
 
NET REVENUES
  $ 401,620  
  $ 97,318  
    304,302  
    312.69 %
OPERATING EXPENSES:
       
       
       
       
General and Administrative
    515,875
    1,217,050  
    (701,175 )
    -57.61 %
Professional Fees
    157,976  
    322,215  
    (164,239 )
    -50.97 %
Officer's Salary
    528,127  
    444,596  
    83,531  
    18.79 %
Rent - Related Party
    11,520  
    10,560  
    960  
    9.09 %
Research and Development
    148,069  
    258,892  
    (110,823 )
    -42.81 %
Total operating expenses
    1,361,567
    2,253,313  
    (891,746 )
    -39.57 %
Loss from operations
    (959,947 )
    (2,155,995 )
    1,196,048
    -55.48 %
Gain on forgiveness of debt
    19,924  
    -  
    19,924  
    100.00 %
Interest expense
    (228,954 )
    (177,105 )
    (51,849 )
    29.28 %
Net Loss
  $ (1,168,977 )
  $ (2,333,100 )
    1,164,123
    -49.90 %
 
 
  Net Revenues :    During the year ended December 31, 2018, we realized $401,620 of revenues from our business. During the year ended December 31, 2017, we realized $97,318 of revenues from our business. The change in revenues between the years ended December 31, 2018 and 2017 was $304,302 or 312.69%.   This increase was related to the US Defense Department exercise of our contract option extension and increased funding levels. 
 
Research and development expenses:    During year ended December 31, 2018 we incurred $148,069 research and development expenses.   During year ended December 31, 2017 we incurred $258,892 of research and development expenses, a decrease of $110,823 or 42.81% compared with the same period in 2017. The research and development expenses are attributable to the research and development with the Notre Dame University; the decrease was due to the timing of research related activity and reduced costs by insources the Company's research operations.
 
Professional Fees:    During year ended December 31 2018, we incurred $157,976 professional expenses, which decreased by $164,239 or 50.97% from $322,215 for year ended December 31, 2017.   The decrease in professional fees expense was attributable to decreased expenses related to investor relations services during year ended December 31, 2018. 
 
10
 
 
Officers Salary:    During year ended December 31, 2018, officers salary expenses increased to $528,127 or 18.79% compared to $444,596 for year ended December 31, 2017.  
 
General and Administrative Expense : General and administrative expenses decreased by $701,175 or 57.61% to $515,875 for year ended December 31, 2018 from $1,217,050 for year ended December 31, 2017.   Our general and administrative expenses for year ended December 31, 2018 consisted of consulting fees of $26,538 and other general and administrative expenses (which includes expenses such as Auto, Business Development, SEC Filing, Investor Relations, General Office, warrant Compensation) of $325,897, Travel of $19,141, office salary of $144,299 for a total of $515,875. Our general and administrative expenses for year ended December 31, 2017 consisted of salaries and benefits of $55,852, consulting fees of $81,280, and other general and administrative expenses (which includes expenses such as: Auto, Business Development, SEC Filing, Investor Relations, General Office, warrant Compensation of $1,048,939, and travel of $30,979 for a total of $1,217,050. The primary reason for the decrease in comparing year ended December 31, 2018 to the corresponding period for 2017 was mainly due to general business expenses and warrants issuances for services.
 
Rent – Related Party:    During the year ended December 31 2018, rent- related party expense increased to $11,520 or 9.09 % compared to $10,560 for the year ended December 31, 2017.   The increase in rent-related party expense was attributable to the additional month of rent recorded in 2018.
 
Gain on Forgiveness of Debt :    Gain on forgiveness of debt increased by $19,924 to $19,924 for the year ended December 31, 2018 compared to $0 for the year ended December 31, 2017.   The increase was primarily due to the issuance of stock as payment for consulting services.
 
Interest Expense :    Interest expense increased to $228,954, or 29.27% for the year ended December 31, 2018 compared to $177,105 for the year ended December 31, 2017.   The increase was primarily due to interest on the related party loans and accounts payable and accrued expenses to the related parties.
 
Net Loss :   Net loss decreased by $1,164,123, or 49.90%, to a net loss of $1,168,977 for the year ended December 31, 2018 from a net loss of $2,333,100 for the year ended December 31, 2017. This decrease in net loss was driven primarily by decreases in research and development, warrant compensation, and professional fees.

Capital Resources and Liquidity
 
Our financial statements have been presented on the basis that we have a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.   As presented in the financial statements, we incurred a net loss of $1,168,977 during the year ended December 31, 2018, and losses are expected to continue in the near term.   The accumulated deficit is $26,888,056 at December 31, 2018.   Refer to Note 2 for our discussion of stockholder deficit.   We have been funding our operations through private loans and the sale of common stock in private placement transactions.   Refer to Note 5 and Note 7 in the financial statements for our discussion of notes payable and shares issued, respectively. Our cash resources are insufficient to meet our planned business objectives without additional financing.   These and other factors raise substantial doubt about our ability to continue as a going concern.   The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of our company to continue as a going concern.
 
Management anticipates that significant additional expenditures will be necessary to develop and expand our business before significant positive operating cash flows can be achieved.   Our ability to continue as a going concern is dependent upon our ability to raise additional capital and to ultimately achieve sustainable revenues and profitable operations.   At December 31, 2018, we had $13,697 of cash on hand.   These funds are insufficient to complete our business plan and as a consequence, we will need to seek additional funds, primarily through the issuance of debt or equity securities for cash to operate our business.   No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to us.   Even if we are able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing or cause substantial dilution for our stockholders, in the case of equity financing.
 
Management has undertaken steps as part of a plan to improve operations with the goal of sustaining our operations for the next twelve months and beyond.   These steps include (a) raising additional capital and/or obtaining financing; (b) controlling overhead and expenses; and (c) executing material sales or research contracts.   There can be no assurance that the Company can successfully accomplish these steps and it is uncertain that the Company will achieve a profitable level of operations and obtain additional financing.   There can be no assurance that any additional financing will be available to the Company on satisfactory terms and conditions, if at all.   As of the date of this Report, we have not entered into any formal agreements regarding the above.
 
In the event the Company is unable to continue as a going concern, the Company may elect or be required to seek protection from its creditors by filing a voluntary petition in bankruptcy or may be subject to an involuntary petition in bankruptcy.   To date, management has not considered this alternative, nor does management view it as a likely occurrence.
 
 
11
 
Cash, total current assets, total assets, total current liabilities and total liabilities as of December 31, 2018 as compared to December 31, 2017, were as follows:
 
 
 
December 31, 2018
 
 
December 31, 2017
 
Cash
  $ 13,697  
  $ 18,150  
Accounts receivable
  $ -  
  $ 25,872  
Prepaid expenses
  $ 6,858
  $ 4,465  
Total current assets
  $ 20,555
  $ 48,487  
Total assets
  $ 71,383
  $ 114,499  
Total current liabilities
  $ 4,530,606
  $ 3,490,305  
Total liabilities
  $ 4,530,606
  $ 3,490,305  

At December 31, 2018, we had a working capital deficit of $4,510,051, compared to a working capital deficit of $3,441,818 at December 31, 2017.   Current liabilities increased to $4,530,606 at December 31, 2018 from $3,490,305 at December 31, 2017, primarily as a result of primarily as a result of accounts payable and accrued compensation.
 
For the year ended December 31, 2018, net cash used in operations of $235,005 was the result of a net loss of $1,168,977 offset by offset by depreciation expense of $ 26,632 , gain on forgiveness of debt of $ 19,924 , imputed interest on related party loans of $11,909, warrants issued to consultants of $ 72,575 , decrease in accounts receivable of $ 25,872 , and an increase in other receivable of $2,394, an increase of accrued expenses and other payables-related party of $682,976 , an increase in accounts payable of $136,326. For the year ended December 31, 2017, net cash used in operations of $729,542 was the result of a net loss of $2,333,100 offset by depreciation expense of $20,291, imputed interest on related party loans of $2,623, warrants issued to related parties of $17,473, warrants issued to consultants of $848,011, increase in prepaid expenses of $6,658, decrease in accounts receivable of $5,986, an increase of accrued expenses and other payables-related party of $551,237, and an increase in accounts payable of $164,595. 
  
Net cash used in our investing activities were $11,448 and $31,167 for the year ended   December 31, 2018 and December 31, 2017, respectively.   Our investing activities for the years ended December 31, 2018 and 2017 are attributable to purchases of fixed assets.
 
Our financing activities resulted in a cash inflow of $242,000 for the year ended December 31, 2018, which is represented by shareholder loan payable. Our financing activities resulted in cash inflow of $480,000 for the year ended December 31, 2017, which is represented by $450,000 proceeds from issuance of common stock and $30,000 proceeds from shareholder note payable.
 
Critical Accounting Policies
 
Our financial statements and related public financial information are based on the application of accounting principles generally accepted in the United States ( GAAP ). GAAP requires the use of estimates; assumptions, judgments and subjective interpretations of accounting principles that have an impact on the assets, liabilities, and revenue and expense amounts reported. These estimates can also affect supplemental information contained in our external disclosures including information regarding contingencies, risk and financial condition. We believe our use of estimates and underlying accounting assumptions adhere to GAAP and are consistently and conservatively applied. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions or conditions. We continue to monitor significant estimates made during the preparation of our financial statements.
 
Our significant accounting policies are summarized in Note 1 of our financial statements. While all these significant accounting policies impact its financial condition and results of operations, we view certain of these policies as critical. Policies determined to be critical are those policies that have the most significant impact on our financial statements and require management to use a greater degree of judgment and estimates. Actual results may differ from those estimates. Our management believes that given current facts and circumstances, it is unlikely that applying any other reasonable judgments or estimate methodologies would cause effect on our results of operations, financial position or liquidity for the periods presented in this report.
  
Recent Accounting Pronouncements
 
In February 2018, the FASB issued ASU No. 2018-02, Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income . The guidance permits entities to reclassify tax effects stranded in Accumulated Other Comprehensive Income as a result of tax reform to retained earnings. This new guidance is effective for annual and interim periods in fiscal years beginning after December 15, 2018. Early adoption is permitted in annual and interim periods and can be applied retrospectively or in the period of adoption. We are evaluating the impact of adopting this guidance on our Consolidated Financi al Statements.    
 
In March 2018, the FASB issued ASU No. 2018-05, Income Taxes (Topic 740) - Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118. The amendment provides guidance on accounting for the impact of the Tax Cuts and Jobs Act (the “Tax Act”) and allows entities to complete the accounting under ASC 740 within a one-year measurement period from the Tax Act enactment date. This standard is effective upon issuance. The Tax Act has several significant changes that impact all taxpayers, including a transition tax, which is a one-time tax charge on accumulated, undistributed foreign earnings. The calculation of accumulated foreign earnings requires an analysis of each foreign entity’s financial results going back to 1986. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements.
 
 
12
 
 
In June 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting ,  which  expands  the  scope  of  Topic  718  to  include  share-based  payment transactions  for  acquiring  goods  and  services  from  nonemployees.  An  entity  should  apply  the  requirements  of  Topic  718  to  nonemployee  awards  except  for specific guidance on inputs to an option pricing model and the attribution of cost (that is, the period of time over which share-based payment awards vest and the pattern of cost recognition over that period). The new guidance is effective for all entities for annual periods, and interim periods within those annual periods, beginning  after  December  15,  2017,  with  early  adoption  permitted.  We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements.  
 
In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820), Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement. The amendments in this Update modify certain disclosure requirements of fair value measurements and are effective for all entities for fiscal years,  and  interim  periods  within  those  fiscal  years,  beginning  after  December  15,  2019.  Early  adoption  is  permitted.  We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements.

In January 2017, the FASB issued Accounting Standards Update ( ASU ) 2017-04, Intangibles Goodwill and Other (Topic 350). The amendments in this update simplify the test for goodwill impairment by eliminating Step 2 from the impairment test, which required the entity to perform procedures to determine the fair value at the impairment testing date of its assets and liabilities following the procedure that would be required in determining fair value of assets acquired and liabilities assumed in a business combination. The amendments in this update are effective for public companies for annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements.
 
In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805); Clarifying the Definition of a Business. The amendments in this update clarify the definition of a business to help companies evaluate whether transactions should be accounted for as acquisitions or disposals of assets or businesses. The amendments in this update are effective for public companies for annual periods beginning after December 15, 2017, including interim periods within those periods. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements.
 
In July 2017, the Financial Accounting Standards Board ( FASB ) issued Accounting Standards Update ( ASU ) No. 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815). The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments.
 
As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). The amendments in Part II of this Update recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception.
 
Those amendments do not have an accounting effect. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted for all entities, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The Company is currently reviewing the impact of adoption of ASU 2017-11on its financial statements.
 
All other newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable  
 
Off-Balance Sheet Arrangements
 
We do not have any off-balance sheet arrangements, financings, or other relationships with unconsolidated entities or other persons, also known as special purpose entities (SPEs).
 
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.
 
As the Company is a smaller reporting company, this item is  not applicable.
 
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.
 
CONTENTS
 
PAGE
  14
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
 
 
 
PAGE
  15
BALANCE SHEETS AS OF DECEMBER 31, 2018 AND DECEMBER 31, 2017.
 
 
 
PAGE
  16
STATEMENTS OF OPERATIONS FOR THE YEARS ENDED DECEMBER 31, 2018 AND DECEMBER 31, 2017.
 
 
 
PAGE
  17
STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED DECEMBER 31, 2018 AND DECEMBER 31, 2017.
 
 
 
PAGES
  18
STATEMENT OF CHANGES IN STOCKHOLDERS DEFICIT FOR THE PERIOD FROM DECEMBER 31, 2016 TO DECEMBER 31, 2018.
 
 
 
PAGES
  19
NOTES TO FINANCIAL STATEMENTS.
 
 

 
13
 
 
 
 
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
 
 
To the Board of Directors and
Stockholders of Kraig Biocraft Laboratories, Inc.
 
Opinion on the Financial Statements
 
  We have audited the accompanying consolidated balance sheets of Kraig Biocraft Laboratories, Inc. (the Company) as of December 31, 2018 and 2017, and the related consolidated statements of operations, stockholders’ deficit, and cash flows for each of the years in the two-year period ended December 31, 2018, and the related notes and schedules (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2018 and 2017, and the results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2018, in conformity with accounting principles generally accepted in the United States of America.
 
Basis for Opinion
 
  These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
 
  We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.
 
Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
 
The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company suffered a net loss from operations and has a net capital deficiency, which raises substantial doubt about its ability to continue as a going concern. Management’s plans regarding those matters are described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
 
/s/ M&K CPAS, PLLC
 
We have served as the Company’s audit since 2013.
 
Houston, TX
 
March 29, 2019
 
 
14
 

 
Kraig Biocraft Laboratories, Inc. and Subsidiary
 
 
Consolidated Balance Sheets
 
 
 
 
 
 
 
 
 
ASSETS
 
 
 
 
 
 
 
 
 
 
December 31, 2018
 
 
December 31, 2017
 
Current Assets
 
 
 
 
 
 
   Cash
  $ 13,697  
  $ 18,150  
Accounts receivable, net
    -  
    25,872  
Prepaid expenses
  6,858
    4,465  
     Total Current Assets
  20,555
    48,487  
 
       
       
Property and Equipment, net
    47,310  
    62,494  
Security deposit
    3,518  
    3,518  
 
       
       
Total Assets
  $ 71,383
  $ 114,499  
 
       
       
 
       
       
 
LIABILITIES AND STOCKHOLDERS' DEFICIT
 
 
       
       
Current Liabilities
       
       
Accounts payable and accrued expenses
  $ 793,482
  $ 678,157  
Note payable - related party
    322,000  
    80,000  
Royalty agreement payable - related party
    65,292  
    65,292  
Accounts payable and accrued expenses - related party
    3,349,832  
    2,666,856  
Total Current Liabilities
    4,530,606
    3,490,305  
 
       
       
Commitments and Contingencies
       
       
 
       
       
Stockholders' Deficit
       
       
  Preferred stock Series A, no par value;
       
       
2 and 2 shares issued and outstanding, respectively
    5,217,800  
    5,217,800  
  Common stock Class A, no par value; unlimited shares authorized,
       
       
816,883,910 and 816,847,910 shares issued and outstanding, respectively
    15,145,798  
    15,144,722  
  Common stock Class B, no par value; unlimited shares authorized,
       
       
no shares issued and outstanding
    -  
    -  
  Common Stock Issuable, 1,122,311 and 1,122,311 shares, respectively
    22,000  
    22,000  
  Additional paid-in capital
    2,043,235  
    1,958,751  
  Accumulated Deficit
    (26,888,056 )
    (25,719,079 )
 
       
       
Total Stockholders' Deficit
    (4,459,223 )
    (3,375,806 )
 
       
       
Total Liabilities and Stockholders' Deficit
  $ 71,383
  $ 114,499  
 
 
 
15
 
 
 
 
Kraig Biocraft Laboratories, Inc. and Subsidiary
 
 
Consolidated Statements of Operations
 
 
 
 
 
 
 
 
 
 
For the Years Ended
 
 
 
December 31, 2018
 
 
December 31, 2017
 
 
 
 
 
 
 
 
Revenue
  $ 401,620  
  $ 97,318  
 
       
       
Operating Expenses
       
       
General and Administrative
    515,875
    1,217,050  
Professional Fees
    157,976  
    322,215  
Officer's Salary
    528,127  
    444,596  
Rent - Related Party
    11,520  
    10,560  
Research and Development
    148,069  
    258,892  
Total Operating Expenses
    1,361,567
    2,253,313  
 
       
       
Loss from Operations
    (959,947 )
    (2,155,995 )
 
       
       
Other Income/(Expenses)
       
       
Gain on forgiveness of debt
    19,924  
    -  
Interest expense
    (228,954 )
    (177,105 )
Total Other Income/(Expenses)
    (209,030 )
    (177,105 )
 
       
       
Net (Loss) before Provision for Income Taxes
    (1,168,977 )
    (2,333,100 )
 
       
       
Provision for Income Taxes
    -  
    -  
 
       
       
Net (Loss)
  $ (1,168,977 )
  $ (2,333,100 )
 
       
       
Net Income (Loss) Per Share - Basic and Diluted
  $ (0.00 )
  $ (0.00 )
 
       
       
Weighted average number of shares outstanding
       
       
  during the period - Basic and Diluted
    816,874,442
    791,393,428  
 
 
 
16
 
 
 
 
Kraig Biocraft Laboratories, Inc. and Subsidiary
 
 
Consolidated Statements of Cash Flows
 
 
 
For the Years Ended December 31,
 
 
 
 
 
 
 
 
 
 
2018
 
 
2017
 
Cash Flows From Operating Activities:
 
 
 
 
 
 
Net Loss
  $ (1,168,977 )
  $ (2,333,100 )
  Adjustments to reconcile net loss to net cash used in operations
       
       
      Depreciation expense
    26,632  
    20,291  
      Gain on forgiveness of debt
    (19,924 )
    -  
      Imputed interest - related party
    11,909  
    2,623  
      Warrants issued to consultants
    72,575  
    848,011  
      Warrants issued to related party
    -  
    17,473  
  Changes in operating assets and liabilities:
       
       
      (Increase) Decrease in prepaid expenses
  (2,394)
    (6,658 )
      (Increase) Decrease in accounts receivables, net
    25,872  
    5,986  
      Increase in accrued expenses and other payables - related party
    682,976  
    551,237  
      Increase in accounts payable
    136,326
 
    164,595  
Net Cash Used In Operating Activities
    (235,005 )
    (729,542 )
 
       
       
Cash Flows From Investing Activities:
       
       
Purchase of Fixed Assets and Domain Name
    (11,448 )
    (31,167 )
Net Cash Used In Investing Activities
    (11,448 )
    (31,167 )
 
       
       
Cash Flows From Financing Activities:
       
       
Proceeds from Notes Payable - related party
    242,000  
    30,000  
Proceeds from issuance of common stock
    -  
    450,000  
Net Cash Provided by Financing Activities
    242,000  
    480,000  
 
       
       
Net Increase in Cash
    (4,453 )
    (280,709 )
 
       
       
Cash at Beginning of Period
    18,150  
    298,859  
 
       
       
Cash at End of Period
  $ 13,697  
  $ 18,150  
 
       
       
Supplemental disclosure of cash flow information:
       
       
 
       
       
Cash paid for interest
  $ 10  
  $ -  
Cash paid for taxes
  $ -  
  $ -  
 
       
       
Supplemental disclosure of non-cash investing and financing activities:
       
       
Shares issued in connection with cashless warrants exercise
  $ -  
  $ 1,703,115  
Shares issued from stock payable
  $ -  
  $ -  
Settlement of accounts payable with stock issuance
  $ 1,076  
  $ 32,850  
 
 
 
17
 
 
 
 
Kraig Biocraft Laboratories, Inc. and Subsidiary
 
 
Conolidated Statement of Changes in Stockholders Deficit
 
 
For the years ended December 31, 2018 and 2017
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Common Stock -
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Class A Shares
 
 
 
 
 
 
 
 
 
 
 
 
Preferred Stock - Series A
 
 
Common Stock - Class A
 
 
 
 
 
Common Stock - Class B
 
 
To be issued
 
 
 
 
 
Accumulated Deficit
 
 
 
 
 
 
 Shares
 
 
Par
 
 
 Shares
 
 
Par
 
 
 
 
 
 Shares
 
 
Par
 
 
Shares
 
 
Par
 
 
APIC
 
 
 
 
 
Total
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Balance, December 31, 2016
    2  
  $ 5,217,800  
    773,627,964  
  $ 12,958,757  
 
    -  
  $ -  
    5,778,633  
  $ 279,754  
  $ 2,568,855  
  $ (23,385,979 )
  $ (2,360,813 )
 
       
       
       
       
       
       
       
       
       
       
       
       
Stock issued for cash ($0.0491/share)
    -  
  $ -  
    9,167,259  
  $ 450,000  
       
    -  
  $ -  
    -  
  $ -  
  $ -  
  $ -  
  $ 450,000  
 
       
       
       
       
       
       
       
       
       
       
       
       
Warrants issued for services - related party
    -  
  $ -  
    -  
  $ -  
       
    -  
  $ -  
    -  
  $ -  
  $ 17,473  
  $ -  
  $ 17,473  
 
       
       
       
       
       
       
       
       
       
       
       
       
Warrants issued for services
    -  
  $ -  
    -  
  $ -  
       
    -  
  $ -  
    -  
  $ -  
  $ 848,011  
  $ -  
  $ 848,011  
 
       
       
       
       
       
       
       
       
       
       
       
       
Exercise of 30,000,000 warrants in exchange for stock
    -  
  $ -  
    29,396,365  
  $ 1,478,211  
       
    -  
  $ -  
       
       
  $ (1,478,211 )
  $ -  
  $ -  
 
       
       
       
       
       
       
       
       
       
       
       
       
Issued shares for warrant exercise issuable as of December 31, 2016
    -  
  $ -  
    3,906,322  
  $ 224,904  
       
    -  
  $ -  
    (3,906,322 )
  $ (224,904 )
  $ -  
  $ -  
  $ -  
 
       
       
       
       
       
       
       
       
       
       
       
       
Issued shares for services issuable as of December 31, 2016
    -  
  $ -  
    750,000  
  $ 32,850  
       
    -  
  $ -  
    (750,000 )
  $ (32,850 )
  $ -  
  $ -  
  $ -  
 
       
       
       
       
       
       
       
       
       
       
       
       
Imputed interest - related party
    -  
  $ -  
    -  
  $ -  
       
    -  
  $ -  
    -  
  $ -  
  $ 2,623  
  $ -  
  $ 2,623  
 
       
       
       
       
       
       
       
       
       
       
       
       
Net loss for the years ended December 31, 2017
    -  
  $ -  
    -  
  $ -  
       
    -  
  $ -  
    -  
  $ -  
  $ -  
  $ (2,333,100 )
  $ (2,333,100 )
 
       
       
       
       
       
       
       
       
       
       
       
       
Balance, December 31, 2017
    2  
  $ 5,217,800  
    816,847,910  
  $ 15,144,722  

    -  
  $ -  
    1,122,311  
  $ 22,000  
  $ 1,958,751  
  $ (25,719,079 )
  $ (3,375,806 )
 
       
       
       
       
       
       
       
       
       
       
       
       
Warrants issued for services
    -  
  $ -  
    -  
  $ -  
       
    -  
  $ -  
    -  
  $ -  
  $ 72,575  
  $ -  
  $ 72,575  
 
       
       
       
       
       
       
       
       
       
       
       
       
Stock issued for services ($0.0299/Sh)
    -  
  $ -  
    36,000  
  $ 1,076  
       
    -  
  $ -  
    -  
  $ -  
  $ -  
  $ -  
  $ 1,076  
 
       
       
       
       
       
       
       
       
       
       
       
       
Imputed interest - related party
    -  
  $ -  
    -  
  $ -  
       
    -  
  $ -  
    -  
  $ -  
  $ 11,909  
  $ -  
  $ 11,909  
 
       
       
       
       
       
       
       
       
       
       
       
       
Net loss for the year ended December 31, 2018
    -  
  $ -  
    -  
  $ -  
       
    -  
  $ -  
    -  
  $ -  
  $ -  
  $ (1,168,977 )
  $ (1,168,977 )
 
       
       
       
       
       
       
       
       
       
       
       
       
Balance, December 31, 2018
    2  
  $ 5,217,800  
    816,883,910  
  $ 15,145,798  

    -  
  $ -  
    1,122,311  
  $ 22,000  
  $ 2,043,235  
  $ (26,888,056 )
  $ (4,459,223 )
 
 
 
18
 
 
 
  Kraig Biocraft Laboratories, Inc.
Notes to Consolidated Financial Statements
As of December 31, 2018 and 2017
 
NOTE 1    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION
 
(A)  Organization
 
 Kraig Biocraft Laboratories, Inc. (the "Company") was incorporated under the laws of the State of Wyoming on April 25, 2006. The Company was organized to develop high strength, protein based fiber, using recombinant DNA technology, for commercial applications in the textile and specialty fiber industries.
 
 On March 5, 2018, the Company issued a board resolution authorizing investment in a Vietnamese subsidiary and appointing a representative for the subsidiary.
 
On April 24, 2018, the Company announced that it had received its investment registration certificate for its new Vietnamese subsidiary Prodigy Textiles Co., Ltd.
 
On May 1, 2018, the Company announced that it had received its enterprise registration certificate for its new Vietnamese subsidiary Prodigy Textiles Co., Ltd.
 
(B) Foreign Currency
 
The assets and liabilities of Prodigy Textiles, Co., Ltd. whose functional currency is the Vietnamese Dong, are translated into US dollars at period-end exchange rates prior to consolidation. Income and expense items are translated at the average rates of exchange prevailing during the period. The adjustments resulting from translating the Company’s financial statements are reflected as a component of other comprehensive (loss) income. Foreign currency transaction gains and losses are recognized in net earnings based on differences between foreign exchange rates on the transaction date and settlement date.
 
(C) Use of Estimates
 
In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period.  Actual results could differ from those estimates.
 
(D) Cash
 
For purposes of the cash flow statements, the Company considers all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents.  There were no cash equivalents as of December 31, 2018 or December 31, 2017.
 
(E) Loss Per Share
 
Basic and diluted net loss per common share is computed based upon the weighted average common shares outstanding as defined by FASB Accounting Standards Codification No. 260, “Earnings per Share.” For December 31, 2018 and 2017, warrants were not included in the computation of income/ (loss) per share because their inclusion is anti-dilutive.
 
The computation of basic and diluted loss per share for December 31, 2018 and September 30, 2017 excludes the common stock equivalents of the following potentially dilutive securities because their inclusion would be anti-dilutive:
 
 
 
December 31, 2018
 
 
September 30, 2017
 
Stock Warrants (Exercise price - $0.001/share)
    36,400,000  
    47,800,000  
Convertible Preferred Stock
    2  
    2  
Total
    36,400,002  
    47,800,002  
 
(F) Research and Development Costs
 
The Company expenses all research and development costs as incurred for which there is no alternative future use. These costs also include the expensing of employee compensation and employee stock based compensation.
 
 
19
 
  Kraig Biocraft Laboratories, Inc.
Notes to Consolidated Financial Statements
As of December 31, 2018 and 2017
(G) Income Taxes
 
The Company accounts for income taxes under FASB Codification Topic 740-10-25 (“ASC 740-10-25”).  Under ASC 740-10-25, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.  Under ASC 740-10-25, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.
 
The net deferred tax liability in the accompanying balance sheets includes the following amounts of deferred tax assets and liabilities:
 
 
 
2018
 
 
2017
 
 
 
 
 
 
 
 
Expected income tax recovery (expense) at the statutory rate of 34% in 2017; 21% in 2018
  $ (1,412,328 )
  $ (793,170 )
Tax effect of expenses that are not deductible for income tax purposes (net of other amounts deductible for tax purposes)
  11,057
    294,265  
Change in valuation allowance
  (1,423,384)
    498,906  
 
       
       
Provision for income taxes
  $ -  
  $ -  
 
       
       
 
The components of deferred income taxes are as follows :
 
 
 
Years Ended    December,
 
 
 
  2018
 
 
  2017
 
 
 
 
 
 
 
 
Deferred tax liability:
  $ -  
  $ -  
Deferred tax asset
       
       
     Net Operating Loss Carryforward
  2,910,863
    4,334,248  
     Valuation allowance
    (2,910,863 )
    (4,334,248 )
     Net deferred tax asset
    -  
    -  
     Net deferred tax liability
  $ -  
  $ -  
 
       
       
   
The valuation allowance was established to reduce the deferred tax asset to the amount that will more likely than not be realized. This is necessary due to the Company’s continued operating losses and the uncertainty of the Company’s ability to utilize all of the net operating loss carryforwards before they will expire through the year 2038.
 
The net change in the valuation allowance for the year ended December 31, 2018 and 2017 was a decrease of $1,412,328 and an increase of $498,906 respectively.
 
On December 22, 2017, the 2017 Tax Cuts and Jobs Act (the Tax Act) was enacted into law and the new legislation contains several key tax provisions that affected us, including a one-time mandatory transition tax on accumulated foreign earnings and a reduction of the corporate income tax rate to 21% effective January 1, 2018, among others. We are required to recognize the effect of the tax law changes in the period of enactment, such as determining the transition tax, remeasuring our U.S. deferred tax assets and liabilities as well as reassessing the net realizability of our deferred tax assets and liabilities. In December 2017, the SEC staff issued Staff Accounting Bulletin No. 118,  Income Tax Accounting Implications of the Tax Cuts and Jobs Act  (SAB 118), which allows us to record provisional amounts during a measurement period not to extend beyond one year of the enactment date. Since the Tax Act was passed late in the fourth quarter of 2017, and ongoing guidance and accounting interpretation are expected over the next 12 months, we consider the accounting of the transition tax, deferred tax re-measurements, and other items to be incomplete due to the forthcoming guidance and our ongoing analysis of final year-end data and tax positions. We expect to complete our analysis within the measurement period in accordance with SAB 118.
 
Effective January 1, 2009, the Company adopted guidance regarding accounting for uncertainty in income taxes. This guidance clarifies the accounting for income taxes by prescribing the minimum recognition threshold an income tax position is required to meet before being recognized in the financial statements and applies to all federal or state income tax positions. Each income tax position is assessed using a two-step process. A determination is first made as to whether it is more likely than not that the income tax position will be sustained, based upon technical merits, upon examination by the taxing authorities. If the income tax position is expected to meet the more likely than not criteria, the benefit recorded in the financial statements equals the largest amount that is greater than 50% likely to be realized upon its ultimate settlement. As of December 31, 2018 and December 31, 2017 there were no amounts that had been accrued in respect to uncertain tax positions.
  
 
20
 
 
  Kraig Biocraft Laboratories, Inc.
Notes to Consolidated Financial Statements
As of December 31, 2018 and 2017
 
Fair value accounting requires bifurcation of embedded derivative instruments such as conversion features in convertible debt or equity instruments, and measurement of their fair value for accounting purposes. In determining the appropriate fair value, the Company uses the Black-Scholes option-pricing model. In assessing the convertible debt instruments, management determines if the convertible debt host instrument is conventional convertible debt and further if there is a beneficial conversion feature requiring measurement. If the instrument is not considered conventional convertible debt, the Company will continue its evaluation process of these instruments as derivative financial instruments.
 
Once determined, derivative liabilities are adjusted to reflect fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives. In addition, the fair value of freestanding derivative instruments such as warrants, are also valued using the Black-Scholes option-pricing model.
 
(H) Stock-Based Compensation
 
In December 2004, the FASB issued FASB Accounting Standards Codification No. 718,  Compensation – Stock Compensation .  Under FASB Accounting Standards Codification No. 718, companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share-based compensation arrangements include stock options, restricted share plans, performance-based awards, share appreciation rights and employee share purchase plans.  As such, compensation cost is measured on the date of grant at their fair value.  Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant.  The Company applies this statement prospectively.
 
 Equity instruments (“instruments”) issued to other than employees are recorded on the basis of the fair value of the instruments, as required by FASB Accounting Standards Codification No. 718.  FASB Accounting Standards Codification No. 505,  Equity Based Payments to Non-Employees  defines the measurement date and recognition period for such instruments.  In general, the measurement date is when either a (a) performance commitment, as defined, is reached or (b) the earlier of (i) the non-employee performance is complete or (ii) the instruments are vested. The measured value related to the instruments is recognized over a period based on the facts and circumstances of each particular grant as defined in the FASB Accounting Standards Codification.
 
The Company operates in one segment and therefore segment information is not presented.
 
  (I) Recent Accounting Pronouncements
 
In February 2018, the FASB issued ASU No. 2018-02, Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income . The guidance permits entities to reclassify tax effects stranded in Accumulated Other Comprehensive Income as a result of tax reform to retained earnings. This new guidance is effective for annual and interim periods in fiscal years beginning after December 15, 2018. Early adoption is permitted in annual and interim periods and can be applied retrospectively or in the period of adoption. We are evaluating the impact of adopting this guidance on our Consolidated Financi   al Statements.    
 
In March 2018, the FASB issued ASU No. 2018-05, Income Taxes (Topic 740) - Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118. The amendment provides guidance on accounting for the impact of the Tax Cuts and Jobs Act (the “Tax Act”) and allows entities to complete the accounting under ASC 740 within a one-year measurement period from the Tax Act enactment date. This standard is effective upon issuance. The Tax Act has several significant changes that impact all taxpayers, including a transition tax, which is a one-time tax charge on accumulated, undistributed foreign earnings. The calculation of accumulated foreign earnings requires an analysis of each foreign entity’s financial results going back to 1986. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements.
 
In June 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting ,  which  expands  the  scope  of  Topic  718  to  include  share-based  payment transactions  for  acquiring  goods  and  services  from  nonemployees.  An  entity  should  apply  the  requirements  of  Topic  718  to  nonemployee  awards  except  for specific guidance on inputs to an option pricing model and the attribution of cost (that is, the period of time over which share-based payment awards vest and the pattern of cost recognition over that period). The new guidance is effective for all entities for annual periods, and interim periods within those annual periods, beginning  after  December  15,  2017,  with  early  adoption  permitted.  We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements. 
 
In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820), Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement. The amendments in this Update modify certain disclosure requirements of fair value measurements and are effective for all entities for fiscal years,  and  interim  periods  within  those  fiscal  years,  beginning  after  December  15,  2019.  Early  adoption  is  permitted.  We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements.
 
21
 
 
In January 2017, the FASB issued Accounting Standards Update (“ASU”) 2017-04, Intangibles – Goodwill and Other (Topic 350). The amendments in this update simplify the test for goodwill impairment by eliminating Step 2 from the impairment test, which required the entity to perform procedures to determine the fair value at the impairment testing date of its assets and liabilities following the procedure that would be required in determining fair value of assets acquired and liabilities assumed in a business combination. The amendments in this update are effective for public companies for annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements.
 
In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805); Clarifying the Definition of a Business. The amendments in this update clarify the definition of a business to help companies evaluate whether transactions should be accounted for as acquisitions or disposals of assets or businesses. The amendments in this update are effective for public companies for annual periods beginning after December 15, 2017, including interim periods within those periods. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements.
 
In July 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815). The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments.
 
As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt—Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). The amendments in Part II of this Update recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception.
 
 Those amendments do not have an accounting effect. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted for all entities, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The Company is currently reviewing the impact of adoption of ASU 2017-11on its financial statements.
 
 
22
 
  Kraig Biocraft Laboratories, Inc.
Notes to Consolidated Financial Statements
As of December 31, 2018 and 2017
 
All other newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable 
 
The 2017 financial statements have been reclassified to conform to the 2018 presentation.
 
(J) Equipment
 
The Company values property and equipment at cost and depreciates these assets using the straight-line method over their expected useful life. The Company uses a five year life for automobiles.
 
In accordance with FASB Accounting Standards Codification No. 360,  Property, Plant and Equipment , the Company carries long-lived assets at the lower of the carrying amount or fair value. Impairment is evaluated by estimating future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. If the sum of the expected undiscounted future cash flow is less than the carrying amount of the assets, an impairment loss is recognized. Fair value, for purposes of calculating impairment, is measured based on estimated future cash flows, discounted at a market rate of interest.
 
There were no impairment losses recorded for the year ended December 31, 2018 and 2017.
  
(K) Fair Value of Financial Instruments
 
We hold certain financial assets, which are required to be measured at fair value on a recurring basis in accordance with the Statement of Financial Accounting Standard No. 157, “Fair Value Measurements” (“ASC Topic 820-10”).   ASC Topic 820-10 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).  ASC Topic 820-10 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. Level 1 instruments include cash, account receivable, prepaid expenses, inventory and account payable and accrued liabilities. The carrying values are assumed to approximate the fair value due to the short term nature of the instrument.
 
The three levels of the fair value hierarchy under ASC Topic 820-10 are described below:
 
  ° 
Level 1 - Valuations based on quoted prices in active markets for identical assets or liabilities that an entity has the ability to access.  We believe our carrying value of level 1 instruments approximate their fair value at December 31, 2018 and December 31, 2017.
  ° 
Level 2 - Valuations based on quoted prices for similar assets or liabilities, quoted prices for identical assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.
  ° 
Level 3 - Valuations based on inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. We consider depleting assets, asset retirement obligations and net profit interest liability to be Level 3. We determine the fair value of Level 3 assets and liabilities utilizing various inputs, including NYMEX price quotations and contract terms. 
 
23
 
 
  Kraig Biocraft Laboratories, Inc.
Notes to Consolidated Financial Statements
As of December 31, 2018 and 2017
 
 
 
 
December 31, 2018
 
 
 
 
December 31, 2017
 
 
Level 1
  $ -  
  $ -  
Level 2
  $ -  
  $ -  
Level 3
  $ -  
  $ -  
Total
  $ -  
  $ -  
 
  (L) Revenue Recognition
 
During 2017 and the year ended December 31, 2018 the Company’s revenues were generated primarily from a contract with the U.S. Government. The Company performs work under this cost-plus-fixed-fee contract. Under the base phase of that contract the Company produced recombinant spider silk woven into ballistic shootpack panels. Those shootpack panels were delivered to the U.S. Government customer. Under an option period award starting in July 2017, to that original contract, the Company has worked to develop new recombinant silks.
 
Effective January 1, 2018, the Company adopted ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. For the comparative periods, revenue has not been adjusted and continues to be reported under ASC 605 — Revenue Recognition. Under ASC 605, revenue is recognized when the following criteria are met: (1) persuasive evidence of an arrangement exists;(2) the performance of service has been rendered to a customer or delivery has occurred; (3) the amount of fee to be paid by a customer is fixed and determinable; and (4) the collectability of the fee is reasonably assured.
 
For the year ended December 31, 2018 and 2017, the Company recognized $401,620 and $0 respectively in revenue from the Government contract. These revenues were generated for work performed in the development and production of the Company’s recombinant silks under the base and option period phases of our ongoing contract with the US Army.
 
On July 24, 2017, the Company signed a contract option extension with the US Army to research and deliver recombinant spider silk fibers and threads. This contract option increased the total contract award by an additional $921,130 to a total of $1,021,092 and added 12 months to the contract duration. This effort was scheduled to end on September 24, 2018, but the Company requested an extension of this contract option period through April 2019 to complete the work.  The Company has been in communication with the contracting office and is working with them as they determine the best path forward.     Management believes there is a possibility of securing a follow-up contract to complete the delivery of all materials for the contract. The Company is also continuing to pursue additional contract opportunities with the Department of Defense, Department of Energy and other governmental agencies.
 
  ( M) Concentration of Credit Risk
 
The Company at times has cash in banks in excess of FDIC insurance limits. At December 31, 2018 and December 31, 2017, the Company had approximately $0 and $0, respectively in excess of FDIC insurance limits.
 
At December 31, 2018 and December 31, 2017, the Company had a concentration of accounts receivable of:
 
Customer
 
 
December 31, 2018
 
 
 
 
December 31, 2017
 
 
Customer A
    -  
    100 %
Customer A
  $ -  
  $ 25,872  
 
For the year ended December 31, 2018 and 2017, the Company had a concentration of sales of:
 
Customer
 
 
December 31, 2018
 
 
 
 
September 30, 2017
 
 
Customer A
    100 %
    0 %
Customer A
  $ 401,620  
  $ --  
 
For the year ended December 31, 2018 and 2017, the Company booked $0 and $0 for doubtful accounts. 
 
24
 
 
  Kraig Biocraft Laboratories, Inc.
Notes to Consolidated Financial Statements
As of December 31, 2018 and 2017
 
NOTE 2     GOING CONCERN
 
As reflected in the accompanying financial statements, the Company has a working capital deficiency of $4,510,051 and stockholders’ deficiency of $4,459,223 and used $235,005 of cash in operations for year ended December 31, 2018.  This raises substantial doubt about its ability to continue as a going concern.  The ability of the Company to continue as a going concern is dependent on the Company’s ability to raise additional capital and implement its business plan.  The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.
 
Management believes that actions presently being taken to obtain additional funding and implement its strategic plans provide the opportunity for the Company to continue as a going concern.
 
NOTE 3 EQUIPMENT
 
At December 31, 2018 and December 31, 2017, property and equipment, net, is as follows:
 
 
 
 
As of December 31, 2018
 
 
 
 
December 31, 2017
 
 
  Automobile
  $ 41,805  
  $ 41,805  
  Laboratory Equipment
    73,194  
    61,746  
  Office Equipment
    7,260  
    7,260  
Leasehold Improvements
    7,938  
    7,938  
  Less: Accumulated Depreciation
    (82,887 )
    (56,255 )
  Total Property and Equipment, net
  $ 47,310  
  $ 62,494  
 
Depreciation expense for the year ended December 31, 2018 and 2017 was $26,632 and $20,291 respectively.
 
NOTE 4   ACRRUED INTEREST – RELATED PARTY
 
On June 6, 2016, the Company received $50,000 from a principal stockholder.  Subsequently on December 1, 2017, the Company received an additional $30,000 from a principal stockholder. On January 8, 2018 and March 31, 2018 the Company received an additional $100,000 and $15,000, respectively.  On April 26, 2018, the Company received $20,000 from a principal stockholder, $15,000 on June 21, 2018, $15,000 on June 29, 2018, $26,000 on October 1, 2018, $11,000 on October 12, 2018 and $20,000 on October 21, 2018. Pursuant to the terms of the loan, the advance bears an interest at 3%, is unsecured, and due on demand. Total loan payable to principal stockholder for as of December 31, 2018 is $322,000. Pursuant to the terms of the loans, the advances bear an interest at 3%, is unsecured and due on demand.  During the year ended December 31, 2018 the Company recorded $11,909 as an in-kind contribution of interest related to the loan and recorded accrued interest payable of $7,071.  During the year ended December 31, 2017, the Company recorded accrued interest payable of $1,621 and $2,623 as an in-kind contribution of interest related to the loan.
 
NOTE 5 STOCKHOLDERS' DEFICIT
 
(A)       Common Stock Issued for Cash
 
On January 25, 2017, the Company issued 2,678,571 share of common stock for $150,000 ($0.056/share).
 
On April 6, 2017, the Company issued 2,083,333 share of common stock for $100,000 ($0.05/share).
 
 On June 12, 2017, the Company issued 2,268,603 shares of common stock for $100,000 ($0.044/share)
 
On June 15, 2017, the Company issued 2,136,752 shares of common stock for $100,000 ($0.047/share)
 
(B) Common Stock Issued for Services
 
Shares issued for services as mentioned below were valued at the closing price of the stock on the date of grant.
  
On December 30, 2016, the Company recorded 3,906,322 issuable shares with a fair value of $224,904 ($0.0575/share) to two consultants for services rendered. Those shares were issued on January 23, 2017.
 
On January 25, 2017, the Company issued 750,000 shares of common stock previously recorded as common stock issuable for the year end December 31, 2016 (See Note 6 (C)).
 
25
 
 
  Kraig Biocraft Laboratories, Inc.
Notes to Consolidated Financial Statements
As of December 31, 2018 and 2017
 
On April 6, 2018, the Company issued 36,000 shares with a fair value of $1,076 ($0.0299/share) to a consultant as consideration for consulting fees owed from October 1, 2014 through December 31, 2018 of $21,000. The issuance of shares resulted in gain on settlement of accounts payable of $19,924 (See Note 6(B)).
  
  (C) Common Stock Warrants
On January 1, 2016, the Company issued 3-year warrant to purchase 6,000,000 shares of common stock at $0.001 per share to a related party for services to be rendered. The warrants had a fair value of $142,526, based upon the Black-Scholes option-pricing model on the date of grant and vested on February 20, 2017, and became exercisable commencing on February 20, 2018, and for a period expiring on February 20, 2021. During the year ended December 31, 2016, the Company recorded $17,473 as an expense for warrants issued to related party. 
 
 Expected dividends
    0 %
 Expected volatility
    78.58 %
Expected term
 
 
3 years
 
 
 Risk free interest rate
    1.32 %
 Expected forfeitures
    0 %
  
 
On July 26, 2016, the Company issued 4-year warrant to purchase 10,000,000 shares of common stock at $0.001 per share to a consultant for services rendered. The warrants had a fair value of $365,157, based upon the Black-Scholes option-pricing model on the date of grant and are fully vested on the date granted. Warrants became exercisable on July 26, 2018, and for a period of 4 years expiring on July 26, 2022. During the years ended December 31, 2016, the Company recorded $365,157 as an expense for such warrants issued. 
 
 Expected dividends
    0 %
 Expected volatility
    93.6 %
Expected term
 
 
 4 years
 
 
 Risk free interest rate
    1.01 %
 Expected forfeitures
    0 %
 
On July 26, 2016, the Company issued 4-year warrant to purchase 8,000,000 shares of common stock at a price of $0.001 per share to a consultant for services rendered. The warrants had a fair value of $292,126, based upon the Black-Scholes option-pricing model on the date of grant and are fully vested on the date granted. Warrants became exercisable on July 26, 2018, and for a period of 4 years expiring on July 26, 2022. During the years ended December 31, 2016, the Company recorded $292,126 as an expense for such warrants issued. 
 
 Expected dividends
    0 %
 Expected volatility
    93.60 %
 Expected term
 
 
4 years
 
 
 Risk free interest rate
    1.01 %
 Expected forfeitures
    0 %
 
On October 2, 2016, the Company issued 2-year warrant to purchase 2,300,000 shares of common stock at an exercise price of $0.04 per share to a consultant for services rendered. The warrants had a fair value of $68,686, based upon the Black-Scholes option-pricing model on the date of grant and are fully vested on the date granted. Warrants will become exercisable on August 25, 2019, and for a period of 2 years expiring on August 25, 2021. During the year ended December 31, 2016, the Company recorded $68,686 as an expense for such warrants issued (See Note 6(C)).
 
 Expected dividends
    0 %
 Expected volatility
    107.51 %
 Expected term
 
 
2 years
 
 
 Risk free interest rate
    0.82 %
 Expected forfeitures
    0 %
 
 
26
 
 
  Kraig Biocraft Laboratories, Inc.
Notes to Consolidated Financial Statements
As of December 31, 2018 and 2017
 
On December 8, 2016, the Company issued 4-year warrant to purchase 15,000,000 shares of common stock at an exercise price of $0.001 per share to a consultant for services rendered. The warrants had a fair value of $630,259, based upon the Black-Scholes option-pricing model on the date of grant and are fully vested on the date granted. Warrants became exercisable on June 12, 2017, and for a period of 2 years expiring on December 8, 2019. During the years ended December 31, 2016, the Company recorded $630,259 as an expense for warrants.
 
On December 30, 2016, the Company recorded stock issuable of 1,953,161 shares in connection with the cashless exercise of the 1,500,000 warrants.  The shares were subsequently issued on January 23, 2017.
 
On December 30, 2016, the Company recorded stock issuable of 1,953,161 shares in connection with the cashless exercise of the 1,500,000 warrants.  The shares were subsequently issued on January 23, 2017.
 
On February 6, 2017, the Company issued 4-year warrant to purchase 750,000 shares of common stock at an exercise price of $0.03 per share to a consultant for services rendered. The warrants had a fair value of $44,421, based upon the Black-Scholes option-pricing model on the date of grant and are fully vested on March 6, 2018 as long as the employee remains as full time. Warrants will be exercisable on October 6, 2019, and for a period of 3 years expiring on October 6, 2022. During the year ended December 31, 2017, the Company recorded $5,161 as an expense for warrants issued. On May 2, 2017, the Company cancelled a 750,000 share warrant with a consultant as the consultant was terminated and the option expense was recaptured by the Company.  
 
 Expected dividends
    0 %
 Expected volatility
    106.40 %
 Expected term
 
 
3 years
 
 
 Risk free interest rate
    1.43 %
 Expected forfeitures
    0 %
 
On June 26, 2017, the Company issued 2-year warrant to purchase 15,000,000 shares of common stock at an exercise price of $0.001 per share to a consultant for services rendered. The warrants had a fair value of $848,011, based upon the Black-Scholes option-pricing model on the date of grant and are fully vested on the date granted.  Warrants became exercisable on December 26, 2017, and for a period of 2 years expiring on June 26, 2019. During the year ended December 31, 2017, the Company recorded 848,011 as an expense for warrants issued.
 
On July 14, 2017 the Company granted 14,745,203 shares in connection with the cashless exercise of the 15,000,000 warrants. (See Note 6 (C)).
 
 Expected dividends
    0 %
 Expected volatility
    106.57 %
 Expected term
 
 
2 years
 
 
 Risk free interest rate
    1.15 %
 Expected forfeitures
    0 %
 
 
On December 27, 2017, the Company issued of 14,651,162 shares in connection with the cashless exercise of the 15,000,000 warrants. The shares were issued on December 29, 2017. (See Note 6 (C)).
 
 Expected dividends
    0 %
 Expected volatility
    102.65 %
 Expected term
 
 
2 years
 
 
 Risk free interest rate
    1.38 %
 Expected forfeitures
    0 %
 
On February 9, 2018, the Company issued 3-year warrant to purchase 3,000,000 shares of common stock at an exercise price of $0.056 per share to a consultant for services rendered. The warrants had a fair value of $52,660, based upon the Black-Scholes option-pricing model on the date of grant and are fully vested on the date granted.  Warrants will be exercisable on August 9, 2019, and for a period of 2 years expiring on August 9, 2021. During the year ended December 31, 2018, the Company recorded 52,660 as an expense for warrants issued.
 
27
 
 
  Kraig Biocraft Laboratories, Inc.
Notes to Consolidated Financial Statements
As of December 31, 2018 and 2017
 
 Expected dividends
    0 %
 Expected volatility
    96.95 %
 Expected term
 
 
3 years
 
 
 Risk free interest rate
    2.26 %
 Expected forfeitures
    0 %
 
 
On March 20, 2018, the Company issued 4-year warrant to purchase 600,000 shares of common stock at an exercise price of $0.001 per share to a consultant for services rendered. The warrants had a fair value of $19,915, based upon the Black-Scholes option-pricing model on the date of grant and are fully vested on March 20, 2018.  Warrants will be exercisable on March 20, 2019, and for a period of 3 years expiring on March 20, 2022. During the year ended December 31, 2018, the Company recorded $19,915 as an expense for warrants issued.
 
 Expected dividends
    0 %
 Expected volatility
    97.56 %
 Expected term
 
 
4 years
 
 
 Risk free interest rate
    2.65 %
 Expected forfeitures
    0 %
 
 
 
 
Number of
Warrants
 
 
 
 
Weighted Average Exercise Price
 
 
 
 
Weighted Average Remaining Contractual Life (in Years)
 
 
Balance, December 31, 2017
    32,800,000  
 
 
 
    3.0  
Granted
    3,600,000  
    -  
       
Exercised
    -  
    -  
       
 Cancelled/Forfeited
    -  
    -  
       
Balance, December 31, 2018
    36,400,000  
       
    2.9  
 Intrinsic Value
  $ 1,783,600  
       
       
 
For the year ended December 31, 2018, the following warrants were outstanding:
 
 
 
Exercise Price Warrants Outstanding
 
 
 
 
Warrants Exercisable  
 
 
 
 
Weighted Average Remaining Contractual Life  
 
 
 
 
Aggregate Intrinsic Value  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  $ 0.001  
    31,100,000  
    2.9  
  $ 1,523,900  
  $ 0.056  
    3,000,000  
    2.6  
  $ 147,000  
  $ 0.04